Saniona shareholders’ propose new board member: Carl Johan Sundberg
Saniona, a leading biotech company within ion-channel research, announces today that shareholders who together represent approximately 37 per cent of the shares and votes in the company propose Carl Johan Sundberg as a new member of the board of directors. Carl Johan Sundberg, Department of Physiology & Pharmacology at Karolinska Institute, has significant experience with research and with financing in private and public biotech companies in Sweden. The shareholders will vote on his nomination at the Company’s Extraordinary General Meeting on September 4, 2015.
Carl Johan Sundberg, born 1958, is MD and professor at the Department of Physiology & Pharmacology at Karolinska Institute in Stockholm, Sweden. Professor Sundberg co-founded the Karolinska Investment Fund, a €60m biomedical VC fund where he worked from 1999 to 2009 as Investment Manager. Carl Johan heads the Unit for Bio-entrepreneurship at Karolinska Institute, is a member of the International Olympic Committee´s Medical Commission and an elected member of the Royal Swedish Academy of Engineering Sciences (IVA). Carl Johan is member of numerous academic and industry boards including member of the board of Karolinska Development AB, listed on Nasdaq OMX Stockholm and Cobra Biologics LTD.
“Professor Sundberg’s nomination to the board reflects Saniona’s commitment to strengthen the company’s expertise in the Swedish biotech market and investor community. His strong scientific background and experience with bio-entrepreneurship and financing will further enrich our board. His strong link with the biotech community and the finance market in Sweden makes him a welcome new member of our board,” says Claus Bræstrup, Chairman of the Board of Saniona.
For more information please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com
About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with major pharmaceutical companies including Pfizer Inc., as well as Saniona’s Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Idec Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard and 18 employees. Saniona is listed at AktieTorget since April 2014 and has about 2,000 shareholders. The company’s share is traded under the ticker SANION. Read more at www.saniona.com.
Tags: